The 340B Drug Pricing Program is a US federal scheme that requires pharmaceutical manufacturers to sell outpatient drugs at heavily discounted prices to hospitals that serve large numbers of low-income patients. In 2024, spending through the program hit a record $66.3 billion. The discounts, typically 20% to 50% off the standard price, are significant enough that losing access to the program is a serious financial event for any hospital.
To stay in the program, hospitals must follow detailed purchasing rules. The most consequential one is the GPO prohibition: certain hospitals, including disproportionate share hospitals that serve high proportions of low-income patients, children's hospitals, and freestanding cancer hospitals, are barred from buying outpatient drugs through group purchasing organizations while also claiming 340B discounts. A group purchasing organization is essentially a bulk-buying club that hospitals use to get lower prices through collective negotiation. Using one while also claiming 340B discounts on the same drugs is not permitted. Violations can result in removal from the program and repayment obligations to manufacturers.
The compliance problem is genuinely labor-intensive. A single qualifying hospital can spend more than 4,000 staff hours per year just reviewing whether purchases qualify for an exception. Staff must cross-reference purchase records with federal drug shortage notices, professional pharmacy association databases, current inventory levels, and shortage forecasts from other hospitals. This is routine but complex, detail-heavy administrative work, exactly the kind of work that AI handles well.
Bluesight is a pharmacy software company that already serves a large portion of the US hospital market. Its existing products cover drug diversion monitoring (tracking unusual patterns in how controlled substances are handled), cost optimization, shortage management, and 340B compliance tracking. Prism is an AI layer built across those products, rather than a standalone tool.
The first piece, Prism Assistant for ControlCheck, is now live and available. ControlCheck is Bluesight's drug diversion monitoring product, used to flag unusual medication transaction patterns. Before Prism, compliance staff still had to manually pull and assemble everything the software flagged. The AI assistant now lets a user ask questions in plain language and get charts and report drafts in response. Bluesight's internal figures, covering 20 active health systems, report that pre-investigation triage dropped from three hours to about 10 minutes, and that recurring reports fell from around six hours of manual assembly to about 15 minutes.
Those numbers come from Bluesight itself, not an independent audit, so enterprise buyers should treat them as directional rather than guaranteed. The more meaningful question is whether the tool produces outputs auditable enough to satisfy federal review, and the design suggests Bluesight thought carefully about that. The AI gathers records and drafts explanations; a separate, deterministic scoring system evaluates 13 evidence inputs and applies rules to reach the compliance determination. An auditor can inspect the source records, the rules applied, and every tool call the system made.
The more ambitious product is a multi-system GPO compliance agent, planned for later in 2026. This would connect purchasing data, shortage evidence, and 340B eligibility records across three Bluesight products and produce an audit-ready compliance report automatically. Testing against synthetic data showed a 100% invoice discovery rate and 93% evidence accuracy, above the 85% internal target. Synthetic testing is not the same as live production performance, and the company appropriately has not claimed otherwise.
The regulatory backdrop adds real urgency here. A federal court in March 2026 struck down a 12-year-old HRSA policy related to the GPO prohibition, finding the agency had not adequately justified its reasoning. The underlying prohibition remains; the legal status of one purchasing model is temporarily in flux. That uncertainty is itself a compliance management burden: 66.7% of pharmacy leaders responsible for 340B management identified the transition to a rebate model as their most pressing concern, even after a related federal pilot was vacated.
For non-hospital readers, the pattern here is worth noting. The 340B compliance problem is a specific, well-defined administrative task with clear inputs, clear rules, and a clear audit requirement. That structure is exactly where AI assistants add real value without creating meaningful risk. The AI is not making policy judgments; it is assembling evidence and surfacing it faster. Hospital compliance teams still own the policy settings, the thresholds, and the final sign-off. That division of responsibility is the right one, and it is the design any regulated industry should expect from AI tools touching compliance workflows.